Overview

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

Video transcript

M&A in 2021 was an absolute crush, crush to market in many different situations. When we look at life sciences as a whole, we had an average of about 460 deals on a quarterly basis, which was up from 2020, about 405. Healthcare had a huge spike in deals with respect to home care, hospice, personal care, big spike on healthcare IT. That was no surprise, but a lot of traction there. So we're very excited for our M&A in 2022 and look forward to having more of a deeper dive within healthcare and life sciences.

Steve Sapletal

Steve Sapletal

Principal, National Advisory Leader, Life Sciences, KPMG US

+1 612-708-2556